Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1996 Jan;3(1):93–97. doi: 10.1128/cdli.3.1.93-97.1996

Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.

E Grimprel 1, P Bégué 1, I Anjak 1, E Njamkepo 1, P François 1, N Guiso 1
PMCID: PMC170254  PMID: 8770511

Abstract

Three hundred sixty children were tested for pertussis serology 0.5 to 1.58 months after complete whole-cell pertussis vaccination. An immunoblot assay was used to detect serum antibodies to pertussis toxin, filamentous hemagglutinin, adenylate cyclase-hemolysin, and pertactin, and agglutination was used for detection of anti-agglutinogen antibodies. Antibodies against pertussis toxin, pertactin, and agglutinogens decreased rapidly after vaccination but increased secondarily, suggesting exposure to infected persons. In contrast, anti-filamentous hemagglutinin antibodies persisted and anti-adenylate cyclase-hemolysin antibodies increased continuously, suggesting either cross-reaction with non-Bordetella antigens or exposure to Bordetella isolates expressing these two antigens, including Bordetella pertussis. These data suggest that unrecognized pertussis is common in France despite massive and sustained immunization in infants and that vaccinated children become susceptible to infection more than 6 years after their last vaccination.

Full Text

The Full Text of this article is available as a PDF (184.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyama T., Murase Y., Kato T., Iwata T. Efficacy of an acellular pertussis vaccine in Japan. J Pediatr. 1985 Aug;107(2):180–183. doi: 10.1016/s0022-3476(85)80121-9. [DOI] [PubMed] [Google Scholar]
  2. Arciniega J. L., Hewlett E. L., Johnson F. D., Deforest A., Wassilak S. G., Onorato I. M., Manclark C. R., Burns D. L. Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis. 1991 Jan;163(1):135–142. doi: 10.1093/infdis/163.1.135. [DOI] [PubMed] [Google Scholar]
  3. Aricò B., Gross R., Smida J., Rappuoli R. Evolutionary relationships in the genus Bordetella. Mol Microbiol. 1987 Nov;1(3):301–308. doi: 10.1111/j.1365-2958.1987.tb01936.x. [DOI] [PubMed] [Google Scholar]
  4. Ashworth L. A., Robinson A., Irons L. I., Morgan C. P., Isaacs D. Antigens in whooping cough vaccine and antibody levels induced by vaccination of children. Lancet. 1983 Oct 15;2(8355):878–881. doi: 10.1016/s0140-6736(83)90869-3. [DOI] [PubMed] [Google Scholar]
  5. Bass J. W., Wittler R. R. Return of epidemic pertussis in the United States. Pediatr Infect Dis J. 1994 May;13(5):343–345. doi: 10.1097/00006454-199405000-00002. [DOI] [PubMed] [Google Scholar]
  6. Blennow M., Granström M. Long term serologic follow-up after pertussis immunization. Pediatr Infect Dis J. 1990 Jan;9(1):21–26. doi: 10.1097/00006454-199001000-00005. [DOI] [PubMed] [Google Scholar]
  7. Cromer B. A., Goydos J., Hackell J., Mezzatesta J., Dekker C., Mortimer E. A. Unrecognized pertussis infection in adolescents. Am J Dis Child. 1993 May;147(5):575–577. doi: 10.1001/archpedi.1993.02160290081031. [DOI] [PubMed] [Google Scholar]
  8. Farfel Z., Könen S., Wiertz E., Klapmuts R., Addy P. A., Hanski E. Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination. J Med Microbiol. 1990 Jul;32(3):173–177. doi: 10.1099/00222615-32-3-173. [DOI] [PubMed] [Google Scholar]
  9. Guiso N., Grimprel E., Anjak I., Bégué P. Western blot analysis of antibody responses of young infants to pertussis infection. Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):596–600. doi: 10.1007/BF01973637. [DOI] [PubMed] [Google Scholar]
  10. Guiso N., Szatanik M., Rocancourt M. Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization. Microb Pathog. 1991 Dec;11(6):423–431. doi: 10.1016/0882-4010(91)90038-c. [DOI] [PubMed] [Google Scholar]
  11. He Q., Viljanen M. K., Nikkari S., Lyytikäinen R., Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis. 1994 Oct;170(4):873–877. doi: 10.1093/infdis/170.4.873. [DOI] [PubMed] [Google Scholar]
  12. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed) 1988 Feb 27;296(6622):612–614. doi: 10.1136/bmj.296.6622.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Khattak M. N., Matthews R. C. A comparison of the DNA fragment patterns of the mouse-virulent challenge strains and clinical isolates of Bordetella pertussis. J Infect. 1993 Sep;27(2):119–124. doi: 10.1016/0163-4453(93)94566-t. [DOI] [PubMed] [Google Scholar]
  14. Khelef N., Bachelet C. M., Vargaftig B. B., Guiso N. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect Immun. 1994 Jul;62(7):2893–2900. doi: 10.1128/iai.62.7.2893-2900.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Khelef N., Sakamoto H., Guiso N. Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection. Microb Pathog. 1992 Mar;12(3):227–235. doi: 10.1016/0882-4010(92)90057-u. [DOI] [PubMed] [Google Scholar]
  16. Khelef N., Zychlinsky A., Guiso N. Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect Immun. 1993 Oct;61(10):4064–4071. doi: 10.1128/iai.61.10.4064-4071.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Locht C., Geoffroy M. C., Renauld G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. EMBO J. 1992 Sep;11(9):3175–3183. doi: 10.1002/j.1460-2075.1992.tb05394.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ramsay M. E., Rao M., Begg N. T., Redhead K., Attwell A. M. Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine. Lancet. 1993 Jul 24;342(8865):203–205. doi: 10.1016/0140-6736(93)92298-8. [DOI] [PubMed] [Google Scholar]
  19. Relyveld E., Oato N. H., Guérin N., Coursaget P., Huet M., Gupta R. K. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal. Vaccine. 1991 Nov;9(11):843–850. doi: 10.1016/0264-410x(91)90224-t. [DOI] [PubMed] [Google Scholar]
  20. Thomas M. G., Ashworth L. A., Miller E., Lambert H. P. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J Infect Dis. 1989 Nov;160(5):838–845. doi: 10.1093/infdis/160.5.838. [DOI] [PubMed] [Google Scholar]
  21. Van Savage J., Decker M. D., Edwards K. M., Sell S. H., Karzon D. T. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990 Mar;161(3):487–492. doi: 10.1093/infdis/161.3.487. [DOI] [PubMed] [Google Scholar]
  22. Weiss A. A., Hewlett E. L. Virulence factors of Bordetella pertussis. Annu Rev Microbiol. 1986;40:661–686. doi: 10.1146/annurev.mi.40.100186.003305. [DOI] [PubMed] [Google Scholar]
  23. Woolfrey B. F., Moody J. A. Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev. 1991 Jul;4(3):243–255. doi: 10.1128/cmr.4.3.243. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES